Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY21097611,2

Neoplasia

Volumn 13, Issue 6, 2011, Pages 537-549

  Zhang, Mengxian ^a,b,c   Herion, Tobias W ^b   Timke, Carmen ^b   Han, Na ^a   Hauser, Kai ^b   Weber, Klaus J ^c   Peschke, Peter ^b   Wirkner, Ute ^b   Lahn, Michael ^d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LY 2109761; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 79958082880     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11258     Document Type: Article

References (48)

1. DeAngelis LM (2001). Brain tumors. N Engl J Med 344, 114-123.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
3. Derynck R and Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 425, 577-584.
4. Dumont N and Arteaga CL (2003). Targeting the TGFβ signaling network in human neoplasia. Cancer Cell 3, 531-536.
5. Jennings MTand Pietenpol JA (1998). The role of transforming growth factor β in glioma progression. J Neurooncol 36, 123-140.
6. Massagué J (2008). TGF-β in cancer. Cell 134, 215-230.
7. Seoane J (2006). Escaping from the TGFβ anti-proliferative control. Carcinogenesis 27, 2148-2156.
8. 2. J Neurosci 21, 3360-3368.
9. Stiles JD, Ostrow PT, Balos LL, Greenberg SJ, Plunkett R, Grand W, and Heffner RR Jr (1997). Correlation of endothelin-1 and transforming growth factor β-1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 56, 435-439.
10. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I, Salford LG, Sjögren HO, and Widegren B (2000). Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89, 251-258.
11. Jachimczak P, Hessdörfer B, Fabel-SchulteK, WismethC, BryschW, Schlingensiepen KH, Bauer A, Blesch A, and Bogdahn U (1996). Transforming growth factor β mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65, 332-337.
12. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, and Korc M (1993). Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846-1856.
13. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C, Henne-Bruns D, Kremer B, and Kalthoff H (2001). Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7, S925-S932.
14. 1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci 100, 663-670.
15. 3 protein expression in colorectal carcinomas. Strahlenther Onkol 180, 201-208.
16. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, et al. (2007). High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11, 147-160.
17. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et al. (2004). SD-208, a novel transforming growth factor-β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64, 7954-7961.
18. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al. (2006). Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 12, 4315-4330.
19. Zhang B, Halder SK, Zhang S, and Datta PK (2009). Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Cancer Lett 277, 114-120.
20. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, and Chiao PJ (2008). LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7, 829-840.
21. Fransvea E, Angelotti U, Antonaci S, and Giannelli G (2008). Blocking transforming growth factor-β up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47, 1557-1566.
22. Andarawewa KL, Paupert J, Pal A, and Barcellos-Hoff MH (2007). New rationales for using TGFβ inhibitors in radiotherapy. Int J Radiat Biol 83, 803-811.
23. 1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 66, 10861-10869.
24. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH, and Hong SI (2006). Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66, 8511-8519.
25. Wild-Bode C, Weller M, Rimner A, Dichgans J, and Wick W (2001). Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61, 2744-2750.
26. Pepper MS (1997). Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8, 21-43.
27. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J, et al. (2009). Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 69, 836-844.
28. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, et al. (2009). Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 29, 1125-1133.
29. Brix G, Semmler W, Port R, Schad LR, Layer G, and Lorenz WJ (1991). Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15, 621-628.
30. Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, et al. (1999). Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 8, 2604-2613.
31. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, and Schiff R (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99, 694-705.
32. Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E, et al. (2010). Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol 36, 1367-1377.
33. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, and Short SC (2009). Cytotoxic effects of temozolomide and radiation are additive-and schedule-dependent. Int J Radiat Oncol Biol Phys 75, 1511-1519.
34. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, and Loeffler JS (2006). Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12, 4738-4746.
35. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
36. Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, Ponce F, Coons SW, Giese A, Seiler RW, and Berens ME (2001). Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 7, 2480-2489.
37. Cho SY and Klemke RL (2000). Extracellular regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 149, 223-236.
38. Qian LW, Mizumoto K, Urashima T, Nagai E, Maehara N, Sato N, Nakajima M, and Tanaka M (2002). Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 8, 1223-1227.
39. 1. Br J Cancer 70, 199-203.
40. HjelmelandMD, Hjelmeland AB, Sathornsumetee S, Reese ED, HerbstreithMH, Laping NJ, Friedman HS, BignerDD, Wang XF, and Rich JN (2004). SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3, 737-745.
41. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, and Griffin RJ (2007). Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13, 3395-3402.
42. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, and Dicker AP (2005). Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87MG glioblastoma. Clin Cancer Res 11, 835-842.
43. Koochekpour S, Merzak A, and Pilkington GJ (1996). Vascular endothelial growth factor production is stimulated by gangliosides and TGFβ isoforms in human glioma cells in vitro. Cancer Lett 102, 209-215.
44. 3 integrin expression. Biochem Biophys Res Commun 268, 607-611.
45. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
46. Kiessling F, Krix M, Heilmann M, Vosseler S, Lichy M, Fink C, Farhan N, Kleinschmidt K, Schad L, Fusenig NE, et al. (2003). Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast-enhanced intermittent power Doppler sonography. Invest Radiol 38, 516-524.
47. Huang H, Bhat A, Woodnutt G, and Lappe R (2010). Targeting the ANGPTTIE2 pathway in malignancy. Nat Rev Cancer 10, 575-585.
48. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, and Fukumura D (2010). Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16, 3618-3627.